• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

    85.05 -0.85 (-0.99%)
    Delayed Quote Updated: 9:31 AM EDT, Oct 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 16,949
    Open 85.14
    Bid (Size) 84.20 (200)
    Ask (Size) 86.09 (100)
    Prev. Close 85.90
    Today's Range 84.59 - 85.14
    52wk Range 18.12 - 110.17
    Shares Outstanding 101,192,921
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    52-Week Range 22.8% below 52-week high
    85.05
    18.1252W Low 110.1752W High
    1 Week 7.6% below 1-week high
    77.051W Low 92.081W High

    Spyre Therapeutics, Inc. - Common Stock (SYRE) traded between $18.12 and $110.17 over the past 52 weeks and last traded at $85.05, 22.8% below its 52-week high. Over the past week it ranged between $77.05 and $92.08.

    Past 12 Months
    +6.2%
    -6.3%
    -9.3%
    +34.4%
    +178.1%
    +349.6%
    1W +$4.94
    1M -$5.75
    3M -$8.68
    6M +$21.78
    YTD +$54.47
    1Y +$66.13

    SYRE was +349.6% over the past year, +34.4% over six months, +178.1% year to date, +6.2% in the last week.

    12 Months vs Market
    SYRE
    +349.6%
    DIA
    +13.2%
    SPY
    +17.3%
    QQQ
    +22.9%
    IWM
    +13.6%

    Over the past 12 months SYRE returned +349.6% versus DIA (Dow) +13.2%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +22.9% and IWM (Russell 2000) +13.6%.

    Volume & Liquidity 0.01× 3-mo avg
    Today 16,949 3-mo avg 1.2M
    1W
    2.3M
    1M
    1.6M
    3M
    1.2M
    6M
    1.3M
    YTD
    1.1M
    1Y
    1.1M

    SYRE most recently traded 16,949 shares against a 3-month average daily volume of 1.2M.

    More News

    Read More
    News headline image
    Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Participate in Upcoming September Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    Wednesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Participate in Upcoming June Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
    Via The Motley Fool
    News headline image
    Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
    Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
    The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
    What is the current price of Spyre Therapeutics, Inc. - Common Stock?
    The current price of Spyre Therapeutics, Inc. - Common Stock is 85.05
    When was Spyre Therapeutics, Inc. - Common Stock last traded?
    The last trade of Spyre Therapeutics, Inc. - Common Stock was at 10/13/26 09:31 AM ET
    What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
    The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 8.61B
    How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
    Spyre Therapeutics, Inc. - Common Stock has 9B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.